EquiTech Corporation

EquiTech Corporation

March 10, 2005 08:30 ET

EquiTech Announces Further Clinical Trial Results for its New Ibuprofen Caplet


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: EQUITECH CORPORATION

TSX VENTURE SYMBOL: EQT

MARCH 10, 2005 - 08:30 ET

EquiTech Announces Further Clinical Trial Results for
its New Ibuprofen Caplet

EDMONTON, ALBERTA--(CCNMatthews - March 10, 2005) - EquiTech Corporation
(TSX VENTURE:EQT) today announced further details of its Phase II
clinical trial of ZAG-1701, its novel reformulated ibuprofen caplet
following a review of the results of the clinical trial conducted by
Analgesic Development Ltd of New York with Dr. Abraham Sunshine as the
principal investigator. The primary objective of the study was to
compare the speed of absorption of ibuprofen into the bloodstream of a
400 mg dose of ZAG-1701 with a 400 mg dose of Motrin IB® in patients
experiencing the pain of wisdom tooth extraction.

This study was undertaken because previous work done by EquiTech
scientists suggested that patients in pain absorb drugs more slowly
compared to healthy subjects not in pain. The data from the clinical
study revealed that at 15 minutes after drug dosing, 2.8 times more
ibuprofen entered the blood stream in patients who took ZAG-1701
compared to patients who took Motrin IB® (based on the ratio of the
means of the area-under-the-curve calculations, a reflection of the
extent of absorption). Statistically significant increased absorption
was also observed at 30 minutes where 2.7 times, at 45 minutes where 2.3
times, and at 60 minutes where 2.0 times more ibuprofen entered the
blood stream in patients given ZAG-1701 compared to patients who took
Motrin IB®.

The data also showed that in patients who received ZAG-1701 caplets,
peak concentrations of ibuprofen in the blood stream occurred on average
at 1 hour and 26 minutes compared to 2 hours and 19 minutes for Motrin
IB®.

"These results suggest that, during the first hour and half after drug
administration, when the analgesic effect is most desired, the drug
enters the bloodstream up to 2.8 times more following ZAG-1701 as
compared with Motrin IB®" said Dr. Fakhreddin Jamali, the Chief
Scientific Officer and scientific founder of EquiTech. "The data
supports our science and suggests that ZAG-1701 may be rapidly absorbed
into the blood steam. The result of this study can be extrapolated to
other acute pains because wisdom tooth removal is the accepted industry
standard test to evaluate the effectiveness of pain relief products for
general mild to moderate acute pain."

The Phase II clinical trial was a randomized and single-blinded study
designed to compare a 400 mg dose of ZAG-1701 to the same dose of Motrin
IB® tablets in dental patients who have undergone wisdom tooth
extraction. A total of 26 patients were enrolled in the trial. The trial
was conducted using independent third party clinical research
organizations and experts who also provided the data analysis.

Based on publicly available information, the worldwide pain medication
market was valued at US$38 billion (2002) and is expected to nearly
double to $75 billion by the year 2010.

EquiTech trades on the TSX Venture Exchange under the symbol EQT and
currently has approximately 14.3 million common shares outstanding.

This news release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities in any jurisdiction. The
securities of the corporation have not been and will not be registered
under the U.S. Securities Act, 1933, as amended and subject to certain
exemptions may not be offered or sold in the United States or to U.S.
persons. The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This press
release may contain forward-looking statements, i.e. information that is
not strictly historical, concerning EquiTech's business and prospects.
Forward-looking statements are subject to a number of risks and
uncertainties. Actual events and results may differ materially from
those discussed in this press release, due to factors including
research, development, commercial and market risks.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    EquiTech Corporation
    James A. Chivers-Wilson
    President & CEO
    (780) 430-1633
    Website: www.equitechcorporation.com
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this press release.